Although treatment of RRMM is evolving, an unmet need remains—especially for triple class–exposed* patients.1-3
ABECMA (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
This website is best viewed using the horizontal display on your tablet device.
This website is best viewed using the vertical display on your mobile device.
Although advancements in the treatment of RRMM have transformed outcomes, deep and durable responses remain difficult to achieve after patients have received an IMiD® agent, a PI, and an anti-CD38 antibody.1-3
When patients relapse, their disease becomes increasingly nonresponsive to the 3 main classes of treatments,1,4 resulting in:
Outcomes after
triple-class exposure*
26%-32%
ORR1,2,9,10
2%-3%
≥CR9,10
3-5 months
mPFS1,2,9-11
After receiving multiple lines of therapy, patients’ T cell populations can become compromised, with fewer healthy T cells present. This can lead to12-14:
Although treatment of RRMM is evolving, an unmet need remains—especially for triple class–exposed* patients.1-3
CR=complete response; mPFS=median progression-free survival; ORR=overall response rate; PI=proteasome inhibitor; RRMM=relapsed/refractory multiple myeloma.
Received an IMiD® agent, a PI, and an anti-CD38 antibody.